Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Response01:28

Inflammatory Response

18.4K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
18.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

614
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
614
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

728
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
728
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

917
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
917
T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of real-world evidence research competencies in federated research networks: a maternal health fellowship program evaluation.

JAMIA open·2026
Same author

Outcomes After Acute Respiratory Failure in Patients With Interstitial Lung Disease.

CHEST pulmonary·2026
Same author

Draft genome sequence of <i>Stutzerimonas degradans</i> UO-4-1 isolated from oil-contaminated soil with potential for hydrocarbon degradation.

Microbiology resource announcements·2026
Same author

Evaluating the Effects of a Mobile Obstetric Emergency System on Healthcare Providers' Communication and Relationships in Bong County, Liberia.

Healthcare (Basel, Switzerland)·2026
Same author

Primary culture and characterization of human upper limb muscle satellite cells: an experimental study.

Journal of Yeungnam medical science·2026
Same author

Beyond Membrane Potential: Exploiting Signal Complexity in Genetically Encoded Voltage Indicators.

Sensors (Basel, Switzerland)·2026

Related Experiment Video

Updated: Mar 25, 2026

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

621

Exploring Cyclo (-Gly-Pro) for inflammation modulation in atopic dermatitis: a study on streptococcal postbiotics.

Haeun Lee1, Yunseok Oh2, Tae-Won Seo3

  • 1R&I Center, COSMAX BTI, Inno-Valley E, 255, Pangyo-ro, Bundang-gu, Seongnam-si, 13486, Republic of Korea.

Genes & Genomics
|March 24, 2026
PubMed
Summary

Researchers identified Cyclo (-Gly-Pro), a postbiotic compound from skin bacteria, as a potential treatment for atopic dermatitis (AD). Further research is needed to explore its therapeutic role in managing this chronic skin condition.

Keywords:
StreptococcusAtopic dermatitisCyclo (-Gly-pro)PostbioticSkin microbiome

More Related Videos

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.4K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Related Experiment Videos

Last Updated: Mar 25, 2026

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

621
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.4K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Area of Science:

  • Microbiology
  • Dermatology
  • Biochemistry

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin condition impacting quality of life.
  • AD pathogenesis involves genetic, environmental, and immune factors, with skin barrier defects and Staphylococcus aureus colonization being key.
  • Postbiotics, derived from probiotics, offer potential therapeutic avenues for AD.

Purpose of the Study:

  • To investigate a postbiotic solution from human skin Streptococcus isolates.
  • To identify a core bioactive compound and its therapeutic potential in atopic dermatitis.

Main Methods:

  • Quantification of Cyclo (-Gly-Pro) using GC-MS and GC-FID.
  • Assessment of the compound's impact on inflammatory biomarkers in an AD-like keratinocyte model.
  • Analysis of skin microbiome changes in AD patients post-treatment via 16S V3-V4 amplicon sequencing.

Main Results:

  • Cyclo (-Gly-Pro) was consistently found in all tested Streptococcus strains.
  • Compound production was inversely related to incubation temperature, optimal at 25°C.
  • Optimized production and synergistic effects may enhance therapeutic efficacy.

Conclusions:

  • Findings support further in vivo research for Cyclo (-Gly-Pro) in AD.
  • Elucidating mechanisms can validate its role in novel dermatological therapies.
  • This postbiotic compound shows promise for future AD treatment strategies.